Besides cell‑line licensing, VIVALIS also operates a platform for human‑antibody discovery. The Humalex® platform (from acquired company) allows discovery and production of fully human monoclonal antibodies, suitable for therapeutic or diagnostic use. This expands VIVALIS’s scope beyond manufacturing to more active participation in drug and therapeutic development. Vivalis review